Skip to main content

← Phenome Registry

PH017 — Pleasure & Interest Capacity

Capacity to experience interest, anticipatory pleasure, and consummatory engagement with rewarding or meaningful activities — the functional domain overlapping anhedonia in depressive and related conditions.

How readily interest and pleasure in activities can be felt and sustained — distinct from raw motivation to start tasks or reward-seeking behaviour.

Therapeutic areas: TA001 ★TA002TA003TA007

Provenance: Introduced in registry v3 (2026) following cross-TA depression gap analysis. Benchmarked against RDoC Positive Valence Systems (reward valuation, consummatory pleasure / anhedonia) to remain distinct from Reward Regulation (PH009), Motivation/Drive (PH002), and Behavioural Activation (PH010). (origin: BRAIN)

Related phenomes: PH002 — Motivation / Drive, PH009 — Reward Regulation, PH010 — Behavioural Activation

External framework cross-references

RDoC domains

  • Positive Valence Systems — reward valuation
  • Positive Valence Systems — initial response to reward / consummatory pleasure

DSM / ICD context

  • Major depressive disorder — anhedonia
  • Bipolar disorder — reduced pleasure capacity

Foundational Evidence

Registry-level Phenome Evidence Confidence (below) is independent of Biology → Phenome Confidence and Evidence Confidence on individual mechanism pages. Use the scoring guide for definitions of all three scores.

These are three independent scores. They are not combined or averaged. A phenome can have Medium registry evidence while individual mechanism rows show different Biology → Phenome and Evidence scores.

1. Phenome Evidence Confidence (Phenome Registry only)

Question: How convincing is the foundational evidence that this phenome is a valid, well-defined functional construct — and that diet-relevant biology can plausibly connect to it?

Not a roll-up of Biology → Phenome Confidence or Evidence Confidence from Primary Mechanism page rows. Those are scored per mechanism; this score is assigned once per phenome at registry level.

Derived from foundational landmark evidence organised in up to three layers: construct validation, biology→phenome linkage, and nutrition→biology modulation. Each layer may include one or many landmark papers depending on registry review.

2. Biology → Phenome Confidence (Primary Mechanism page §3 rows)

Question: If this PM/FM biology were substantially impaired in isolation, how directly would that phenome be expected to suffer — within BRAIN architecture?

How it is derived: Reviewers read the PM/FM definition and biological function first — initially ignoring attached references and whether dietary intervention studies exist. References are reviewed only when scoring Evidence Confidence (below).

Score levels (the value shown on each row as Biology → Phenome Confidence):

  • High — primary biological determinant (e.g. noradrenergic signalling → attention; GABA synthesis → calming tone)
  • Medium — major contributory determinant, not the sole driver
  • Low–Medium — established but indirect, modulatory, or one integrative step removed
  • Low — distal, conditional, or weak biological coupling

“Not dietary treatment efficacy” means this score does not ask whether a diet or supplement treats the phenome. It asks whether the biology itself is architecturally relevant. Limited dietary RCT evidence belongs in Evidence Confidence, not here.

3. Evidence Confidence (Primary Mechanism page §3 rows)

Question: How convincing are the attached Key References on that specific row that this biology actually relates to this phenome?

How it is derived: Assigned after Biology → Phenome Confidence, by reviewing only the references on that PM/FM row. Judges whether refs support the relationship — not just mechanism or phenome in isolation.

  • High — strong convergent human evidence directly linking mechanism biology to phenome variation
  • Medium — multiple human lines supporting the relationship; may include one bridge study with an inferential step
  • Low–Medium — convergent translational stack without direct mechanism↔phenome measurement on the row
  • Low — mechanistic or preclinical only; mechanism and phenome supported separately but not bridged

Often equal to or lower than Biology → Phenome Confidence. Can occasionally be higher when outcome evidence is stronger than the mechanism's contributory role.

Phenome Evidence Confidence: Low–Medium

Construct and biology→phenome layers are review- and mechanistic-heavy; Jackson (2021) adds human intervention support for mood/pleasure domains without isolating anhedonia as a primary endpoint.

Construct landmark papers

  • Gruber et al. (2023) — Reviews insulin–dopamine reward-processing disruption in depression pathophysiology.
  • Lopresti & Drummond (2014) — Systematic review of saffron clinical studies and antidepressant mechanisms — pleasure/mood construct validation.

Biology → phenome landmark papers

  • Gruber et al. (2023) — Brain dopamine signalling and reward processing as underexplored depression mechanisms.
  • Song et al. (2023) — Mitochondrial dysfunction in depression — adjacent biology for reward-energy integration.

Nutrition → biology landmark papers

  • Jackson et al. (2021) — Saffron RCT reported reduced depression scores and improved social well-being in subclinical mood contexts.
  • Ferguson et al. (2014) — Omega-3 PUFA modulates inflammatory and resolution-phase biology intersecting mood pathways.

Connected mechanisms

BRS1

BRS3